TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01930838

Intervention type: PROCEDURE
Intervention: Gastric bypass operation
Study: NCT01986608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide infusion
Description: Strength: 10 mg/mL for infusion~Form: solution for infusion~Dosage: 200 mg, single dose~Duration: 30-minute infusion or 60-minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide infusion
Description: Strength: 10 mg/mL for infusion~Form: solution for infusion~Dosage: 200 mg, single dose~Duration: 30-minute infusion or 60-minute infusion
Study: NCT02598362

Intervention type: DRUG
Group type: OTHER
Intervention: ciprofloxacin
Description: Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration

Intervention type: DRUG
Group type: OTHER
Intervention: ciprofloxacin
Description: Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
Study: NCT03593109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Description: Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
Study: NCT01986608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide oral
Description: Strength: 200 mg~Form: film-coated tablet~Dosage: 200 mg, single dose~Duration: single oral intake
Study: NCT03373838

Intervention type: OTHER
Intervention: Census
Description: Survey and interview

Intervention type: OTHER
Intervention: Census
Description: Survey and interview
Study: NCT03071393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypoxia via Hypoxico Hyp-123
Description: During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypoxia via Hypoxico Hyp-123
Description: During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham via Hypoxico Hyp-123
Description: During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham via Hypoxico Hyp-123
Description: During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
Study: NCT01272635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Azithromycin
Description: Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Azithromycin
Description: Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Prednisolone
Description: Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Prednisolone
Description: Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
Study: NCT03029923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)
Description: All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation plus Health and Wellness
Description: All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
Study: NCT03258775

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water intake
Description: After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water intake
Description: After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized
Study: NCT00005773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had \<=20 mm Hg increase in PaO2 (less than full response).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard iNO therapy
Description: Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).
Study: NCT01121432

Intervention type: PROCEDURE
Intervention: endobronchial ultrasound-guided transbronchial needle aspiration
Description: One time for aspiration/biopsy. The duration about 1-2 hour.
Study: NCT02135237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prize Contingency Management for Alcohol Abstinence
Description: The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Study: NCT04085497

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment
Description: KT application: KT application includes 2 stages. The banding in the first step is directed to the patellar tendon in order to absorb the load of the knee. The second step is directed directly on the medial plica to benefit from its analgesic effect. For the first step, an I-band is measured from the top of the patella to the tuberositas tibia. I-band is 6 cm wide and 5 mm thick. This I-band is cut into Y-band. First, the part of the band above the patella is pasted with 10% tension. Then the patient's knee is flexed to maximum flexion and the tails of the band are pasted around the patella with 0% tension. The tails of the band are combined together on the tuberositas and completed. For the second step, 4 I-bands 8 cm long and 1.5 cm wide are prepared. The middle of the I-bands is attached to the medial plica with a 0% tension, giving a star shape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: KT application: KT application includes 2 stages. The banding in the first step is directed to the patellar tendon in order to absorb the load of the knee. The second step is directed directly on the medial plica to benefit from its analgesic effect. For the first step, an I-band is measured from the top of the patella to the tuberositas tibia. I-band is 6 cm wide and 5 mm thick. This I-band is cut into Y-band. First, the part of the band above the patella is pasted with 10% tension. Then the patient's knee is flexed to maximum flexion and the tails of the band are pasted around the patella with 0% tension. The tails of the band are combined together on the tuberositas and completed. For the second step, 4 I-bands 8 cm long and 1.5 cm wide are prepared. The middle of the I-bands is attached to the medial plica with a 0% tension, giving a star shape.
Study: NCT03222297

Intervention type: DEVICE
Intervention: early skull repair
Description: Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.

Intervention type: DEVICE
Intervention: late-stage skull repair
Description: Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
Study: NCT03461640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based doula support for labour
Description: CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based doula support for labour
Description: CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard labour support
Description: Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard labour support
Description: Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation.
Study: NCT04425382

Intervention type: DRUG
Intervention: Darunavir/Cobicistat
Description: Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily

Intervention type: DRUG
Intervention: Lopinavir/Ritonavir
Description: Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily
Study: NCT01363908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602
Study: NCT02967510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03079596

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERAS perioperative cares
Description: Patient's preoperative counseling \& education before surgery No Bowel preparation Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Fluid restriction \& Management by pulse contour analysis or transesophageal doppler Early mobilization Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD)) Epidural patient controlled analgesics (no opioids analgesics) Postoperative Nausea Active Control Thromboembolism prophylaxis by low molecular weighted heparin (LMWH) Perioperative High content Oxygen therapy No drain insertion No Levin tube Patients will be discharged at POD#4 if there's no problem.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional perioperative cares
Description: No Patient's preoperative counseling \& education before surgery Bowel preparation No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Conventional Fluid Management by clinical signs (Urine output, heart rate etc.) Conventional Mobilization Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD) IV PCA Postoperative Nausea Control if needed No Thromboembolism prophylaxis No or Low Content Oxygen therapy Routine drain insertion Levin tube insertion if needed
Study: NCT04239742

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F18-fluciclovine PET/CT
Description: 370 MBq ±10% 18F-Fluciclovin + low-dose CT scan, from skull base to pelvis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F18-PSMA-1007 PET/CT
Description: 4 MBq/kg ±10% F18-PSMA + low-dose CT scan, from skull base to pelvis
Study: NCT01221701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Psychology
Description: Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and 1 booster session provided 1 month after the 15th session.
Study: NCT00890617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy (PTC)
Description: CT-guided PTC with the intent to eradicate the entire tumor(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure
Study: NCT01707056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black Coffee
Description: Taking Synthroid with 12 ounces of black coffee for 6 weeks.
Study: NCT04008290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6 mg Liraglutide
Description: For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
Study: NCT01911546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus + low-dose tacrolimus
Description: Patients are supplied everolimus (Zortress) + prograf
Study: NCT03108352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept ophthalmic injection
Description: Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Conbercept ophthalmic injection
Description: Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham/Conbercept ophthalmic injection
Description: Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 \~ 11)
Study: NCT01566448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 20mg/5ml swish and spit four times daily
Study: NCT04283643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Focused Ultrasound
Description: Non-invasive brain stimulation technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Focused Ultrasound
Description: Non-invasive brain stimulation technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Focused Ultrasound
Description: Non-invasive brain stimulation technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation technique
Study: NCT03928951

Intervention type: OTHER
Intervention: General practitioner reassessment of urinary infection antibiotherapy prescribed by emergency departments
Description: Antibiotherapy will be prescribed by emergency physicians and general practitioners will be contacted 4 to 5 days later to know if antibiotherapy was modified
Study: NCT04618120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality-based exercise
Description: Virtual reality-based exercises with Microsoft Xbox 360 Kinect and breathing exercises.~Patient education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Shoulder range of motion, stretching, posture and breathing exercises. Patient education
Study: NCT06390228

Intervention type: PROCEDURE
Intervention: Major hepatectomy
Description: the extent of liver resection
Study: NCT02166489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection autologous mesenchymal stem cells
Description: Intravenous injection of mesenchymal stem cell in patients with PKD
Study: NCT01763775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transtek 125X
Description: Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transtek 125X
Description: Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transtek 950D
Description: Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transtek 950D
Description: Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
Study: NCT04389125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures
Description: One packet once a day, after breakfast, for 12 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 week
Study: NCT04439032

Intervention type: OTHER
Intervention: NanoBone Bone Graft Substitute
Description: Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
Study: NCT01583972

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: retinyl palmitate
Description: 50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
Study: NCT03422120

Intervention type: OTHER
Intervention: Natural Killer Cell Activity Assay
Description: Subjects had a blood test to measure NK cell activity (NKA) at different time points

Intervention type: OTHER
Intervention: Natural Killer Cell Activity Assay
Description: Subjects had a blood test to measure NK cell activity (NKA) at different time points